Many investors treat Kuros Biosciences like a risky drug developer, but the company now makes a bone-graft product that aims to help hospitals get similar patient results while spending less. The story hinges on surgery centers shifting toward lower-cost care, Kuros’s control over its key technology, and a few practical risks that could slow adoption.Read more

DuChemBio already supplies most of South Korea’s Alzheimer’s PET scans, and a big push to build out nuclear medicine treatment capacity could pull the company into a much larger role. The catch is that these projects take time to show up in results, so the key question is whether delays, hospital buildouts, or isotope supply issues derail the upside.Read more

Teladoc looks like a leftover from the pandemic boom, but it now brings in real cash and has a large cash buffer that could change the story. The big question is whether its BetterHelp therapy service can shift from people paying out of pocket to insurance coverage without hurting demand or profits.Read more

Zevra shifts from crowded everyday medicines to ultra-rare diseases, and now sells a first approved treatment for a devastating childhood brain disorder. A one-time cash boost and a growing launch could change how the market views the company—but success depends on finding patients and getting insurers on board.Read more

Zoetis looks dull on Wall Street, but a working veterinarian argues its everyday products and direct-to-clinic sales model create sticky demand that competitors struggle to break. The big question is whether a recent slowdown in clinic visits is a temporary wobble or a warning sign the market is right to be cautious.Read more

Binex wants to shift from a generic drug maker into a global partner for complex biologic medicines, but a repeat history of rule-breaking raises a bigger question: can the company truly change how it operates. The stock looks cheap for reasons that go beyond industry tailwinds, and the next few years hinge on whether management can rebuild trust with regulators and large drugmakers.Read more

Classys looks like more than a one-hit beauty device company, because many clinics keep buying its refill parts after they install a machine. With a wider lineup of treatment technologies and a business that already sells strongly overseas, the story hinges on whether the market is underestimating how durable that demand can be.Read more

Amgen’s obesity-drug excitement may be hiding a bigger problem: key older medicines are shrinking while the company still lacks the production muscle and timing to catch the leaders in weight-loss treatments. If fast-track rules weaken and rivals keep moving faster, the business could struggle to live up to today’s high expectations.Read more

BridgeBio looks like an easy win on paper, but it steps into a crowded fight where the leaders already have doctors, patients, and budgets on their side. The bigger worry is that the whole treatment approach may be shifting, leaving BridgeBio selling yesterday’s kind of medicine just as the market moves on.Read more